Current research predominantly focuses on biomarkers such as PD-L1 (programmed death ligand 1) expression, tumor mutational burden (TMB), microsatellite instability-high (MSI-H), and mismatch repair (MMR) status to predict the efficacy of immunotherapy in patients with advanced gastric cancer (8–11). This evidence concerns the gene CD274 and gastric cancer.